Benjamin Garmezy, MD

Articles

Dr Garmezy on the Impact of Combination Regimens on Outcomes and Quality of Life in Patients With RCC

February 1st 2024

Benjamin Garmezy, MD, discusses the impact of frontline combination regimens on patient outcomes in patients with renal cell carcinoma.

Dr Garmezy on Considerations For Frontline Treatment Selection in ccRCC

January 19th 2024

Benjamin Garmezy, MD, discusses key considerations for the selection of frontline treatment regimens in clear cell renal cell carcinoma.

Dr Garmezy on the Treatment of Patients With Cancer in the Community Setting

November 22nd 2023

Benjamin Garmezy, MD, discusses the treatment of patients with cancer in the community care setting, highlighting the need to include those from this population in enrollment to clinical trials.

Determining the Optimal Use of Adjuvant Immunotherapy in Renal Cell Carcinoma

June 19th 2023

Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year.

Clinical Pearls for Treating Advanced Renal Cell Carcinoma

April 14th 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.

Advanced RCC Treatments Following Prior Immune Checkpoint Inhibitors

April 7th 2023

Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.

TIVO-3 Trial: Tivozanib for Patients With Advanced RCC

April 7th 2023

A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Advanced RCC Treatment Options Post-Progression

March 31st 2023

Experts on renal cell carcinoma discuss post-progression treatment options for RCC.

Considerations in Advanced RCC Treatment Selection

March 31st 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.

Front Line Trials in Advanced RCC

March 24th 2023

Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.

Patient Profile: A 67-Year-Old Man With Metastatic Clear Cell RCC

March 24th 2023

Benjamin Garmezy, MD, presents the case of a 67-year-old man diagnosed with advanced renal cell carcinoma.

Renal Cell Carcinoma Histology and Risk Stratification

March 17th 2023

Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.

Overview of Renal Cell Carcinoma

March 17th 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, open the discussion with an overview of renal cell carcinoma.

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

Precision medicine and personalized medicine are 2 concepts that have pushed their way to the forefront of oncology practice.